Pre-made Ligelizumab benchmark antibody ( Whole mAb, anti-IGHE/IgE therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ligelizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It is an anti-IgE that binds to IGHE an acts as an immunomodulator.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-312-1mg	1mg	3090
GMP-Bios-ab-312-10mg	10mg	Inquiry
GMP-Bios-ab-312-100mg	100mg	Inquiry
GMP-Bios-ab-312-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ligelizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody
INN Name	Ligelizumab
Target	IGHE
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	6uqr:AC
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Novartis;Tanox
Conditions Approved	na
Conditions Active	Urticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid
Conditions Discontinued	Hypersensitivity
Development Tech	na